Enanta Pharmaceuticals, Inc.
 (ENTA)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Yesterday, 4:04 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ1 EPS of $1.36 beats by $0.23.
    • Revenue of $48.4M (-37.5% Y/Y) beats by $1.35M.
    • Press Release
    | Yesterday, 4:04 PM
  • Nov. 24, 2015, 7:28 AM
    • Enanta Pharmaceuticals (ENTA +1.5%) FQ4 results: Revenues: $14.4M (+453.8%); R&D Expense: $7M (+34.6%); SG&A: $3.7M (+32.1%); Operating Income: $3.7M (+169.8%); Net Income: $5.8M (+216.0%); EPS: $0.29 (+207.4%); Quick Assets: $145.2M (+59.9%).
    • FY2015 results: Revenues: $160.9M (+237.3%); R&D Expense: $23.2M (+24.1%); SG&A: $13.5M (+35.0%); Operating Income: $124.1M (+553.2%); Net Income: $79M (+129.7%); EPS: $4.09 (+127.2%); Quick Assets: $145.2M (+59.9%).
    • No guidance given.
    | Nov. 24, 2015, 7:28 AM | 2 Comments
  • Nov. 23, 2015, 4:05 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ4 EPS of $0.29 beats by $0.14.
    • Revenue of $14.42M (+446.2% Y/Y) misses by $2.02M.
    • Press Release
    | Nov. 23, 2015, 4:05 PM
  • Nov. 22, 2015, 5:35 PM
  • Aug. 6, 2015, 5:08 PM
    • Enanta Pharma (NASDAQ:ENTA): FQ3 EPS of $0.13 misses by $0.06.
    • Revenue of $11.6M (-72.4% Y/Y) misses by $4.58M.
    | Aug. 6, 2015, 5:08 PM
  • May 7, 2015, 7:40 AM
    • Enanta Pharma (NASDAQ:ENTA): FQ2 EPS of $1.49 misses by $0.27.
    • Revenue of $57.37M vs. $2.16M in 1Q14 misses by $6.03M.
    | May 7, 2015, 7:40 AM | 2 Comments
  • Feb. 5, 2015, 12:26 PM
    • Enanta Pharmaceuticals (ENTA -1.6%) FQ1 results: Revenues: $77.5M (+999%); R&D Expense: $4.5M (+4.7%); SG&A: $2.8M (+33.3%); Operating Income: $70.2M (+999%); Net Income: $42M (+877.8%); EPS: $2.18 (+826.7%); Quick Assets: $104M (+14.5%).
    • No guidance given.
    | Feb. 5, 2015, 12:26 PM | 1 Comment
  • Feb. 5, 2015, 7:49 AM
    • Enanta Pharma (NASDAQ:ENTA): FQ1 EPS of $2.18 misses by $1.64.
    • Revenue of $77.5M (+8607.9% Y/Y) misses by $6.64M.
    | Feb. 5, 2015, 7:49 AM | 7 Comments
  • Nov. 24, 2014, 8:06 AM
    • Enanta Pharmaceuticals (ENTA -1.1%) FQ4 results: Revenues: $2.6M (+100.0%); Operating Expenses: $8M (+31.1%); Operating Loss: ($5.3M) (-12.8%); Net Loss: ($5M) (-13.6%); Loss Per Share: ($0.27) (-8.0%).
    • FY2014 results: Revenues: $47.7M (+48.6%); Operating Expenses: $28.8M (+25.2%); Operating Income: $19M (+111.1%); Net Income: $34.4M (+621.2%); EPS: $1.80 (+368.7%); Quick Assets: $90.8M (-10.5%).
    • No guidance given.
    | Nov. 24, 2014, 8:06 AM
  • Nov. 24, 2014, 7:36 AM
    • Enanta (NASDAQ:ENTA): FQ4 EPS of -$0.27 beats by $0.06.
    • Revenue of $2.64M (+95.6% Y/Y) misses by $1.17M.
    | Nov. 24, 2014, 7:36 AM
  • Nov. 23, 2014, 5:30 PM
  • Aug. 11, 2014, 9:31 AM
    • Enanta Pharmaceuticals (NASDAQ:ENTA) fiscal Q3 results: Revenues: $42.1M (+999%); Operating Expenses: $7.2M (+22.8%); Operating Income: $34.9M (+935.2%); Net Income: ($50.1M) (+999%); EPS: ($2.61) (+999%); Quick Assets: $95.9M (-5.5%).
    • No financial guidance given.
    | Aug. 11, 2014, 9:31 AM
  • Aug. 11, 2014, 8:00 AM
    • Enanta (NASDAQ:ENTA): FQ3 EPS of $2.61 may not be comparable to consensus of $1.67.
    • Revenue of $42.1M (+2451.5% Y/Y) beats by $1.27M.
    | Aug. 11, 2014, 8:00 AM
  • May 12, 2014, 8:18 AM
    • Enanta Pharmaceuticals (ENTA): FQ2 EPS of -$0.28 misses by $0.74.
    • Revenue of $2.2M (+80.6% Y/Y) misses by $5.95M.
    | May 12, 2014, 8:18 AM
  • Feb. 13, 2014, 8:27 AM
    • Enanta (ENTA): FQ1 EPS of -$0.30 misses by $0.15.
    • Revenue of $0.9M misses by $0.51M.
    | Feb. 13, 2014, 8:27 AM
Company Description
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Company uses its chemistry-driven approach & drug discovery capabilities to develop its products.
Sector: Healthcare
Industry: Biotechnology
Country: United States